The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries
ObjectivesTo investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1332716/full |
| _version_ | 1827325053894656000 |
|---|---|
| author | Rebecca Hasseli Rebecca Hasseli Frank Hanses Melanie Stecher Christof Specker Tobias Weise Stefan Borgmann Martina Hasselberger Bernd Hertenstein Martin Hower Bimba F. Hoyer Carolin Koll Andreas Krause Marie von Lilienfeld-Toal Hanns-Martin Lorenz Uta Merle Susana M. Nunes de Miranda Mathias W. Pletz Anne C. Regierer Jutta G. Richter Jutta G. Richter Siegbert Rieg Christoph Roemmele Maria M. Ruethrich Tim Schmeiser Hendrik Schulze-Koops Anja Strangfeld Maria J.G.T. Vehreschild Florian Voit Reinhard E. Voll Jörg Janne Vehreschild Jörg Janne Vehreschild Ulf Müller-Ladner Alexander Pfeil |
| author_facet | Rebecca Hasseli Rebecca Hasseli Frank Hanses Melanie Stecher Christof Specker Tobias Weise Stefan Borgmann Martina Hasselberger Bernd Hertenstein Martin Hower Bimba F. Hoyer Carolin Koll Andreas Krause Marie von Lilienfeld-Toal Hanns-Martin Lorenz Uta Merle Susana M. Nunes de Miranda Mathias W. Pletz Anne C. Regierer Jutta G. Richter Jutta G. Richter Siegbert Rieg Christoph Roemmele Maria M. Ruethrich Tim Schmeiser Hendrik Schulze-Koops Anja Strangfeld Maria J.G.T. Vehreschild Florian Voit Reinhard E. Voll Jörg Janne Vehreschild Jörg Janne Vehreschild Ulf Müller-Ladner Alexander Pfeil |
| author_sort | Rebecca Hasseli |
| collection | DOAJ |
| description | ObjectivesTo investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared.Methods4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total.ResultsRegarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19.ConclusionInflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease. |
| first_indexed | 2024-03-07T14:14:41Z |
| format | Article |
| id | doaj.art-826148ec9ab2440794ff1f5021a13811 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-07T14:14:41Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-826148ec9ab2440794ff1f5021a138112024-03-06T13:16:58ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-03-011110.3389/fmed.2024.13327161332716The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registriesRebecca Hasseli0Rebecca Hasseli1Frank Hanses2Melanie Stecher3Christof Specker4Tobias Weise5Stefan Borgmann6Martina Hasselberger7Bernd Hertenstein8Martin Hower9Bimba F. Hoyer10Carolin Koll11Andreas Krause12Marie von Lilienfeld-Toal13Hanns-Martin Lorenz14Uta Merle15Susana M. Nunes de Miranda16Mathias W. Pletz17Anne C. Regierer18Jutta G. Richter19Jutta G. Richter20Siegbert Rieg21Christoph Roemmele22Maria M. Ruethrich23Tim Schmeiser24Hendrik Schulze-Koops25Anja Strangfeld26Maria J.G.T. Vehreschild27Florian Voit28Reinhard E. Voll29Jörg Janne Vehreschild30Jörg Janne Vehreschild31Ulf Müller-Ladner32Alexander Pfeil33Section of Rheumatology and Clinical Immunology, Department of Internal Medicine D, University Hospital Münster, Münster, GermanyDepartment of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Giessen, GermanyEmergency Department and Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Regensburg, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, GermanyDepartment of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, GermanyBiocontrol Jena, Jena, GermanyDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, GermanyKlinikum Passau, Passau, GermanyKlinikum Bremen-Mitte, Bremen, Germany0Department of Pneumology, Infectious Diseases, Internal Medicine and Intensive Care, Klinikum Dortmund GmbH, Dortmund, Germany1Department for Rheumatology and Clinical Immunology, University of Schleswig-Holstein, Kiel, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany2Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin, Berlin, Germany3Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany4Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany5Department of Gastroenterology and Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany6Department of Medicine II, University of Freiburg, Freiburg, Germany7Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany8Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany9Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany0Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany1Division of Infectious Diseases, Department of Medicine II, University of Freiburg, Freiburg, Germany2Department of Gastroenterology, Faculty of Medicine, University of Augsburg, Augsburg, Germany3Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany3Private Practice, Cologne, Germany4Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany8Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany5Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany6Department of Internal Medicine II, School of Medicine, University Hospital Rechts Der Isar, Technical University of Munich, Munich, Germany7Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany8Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, GermanyDepartment of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Giessen, Germany9Department of Internal Medicine III, University Hospital Jena, Jena, GermanyObjectivesTo investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared.Methods4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total.ResultsRegarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19.ConclusionInflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease.https://www.frontiersin.org/articles/10.3389/fmed.2024.1332716/fullinflammatory rheumatic diseasesCOVID-19general populationtumor necrosis factor-alpha inhibitorssevere disease |
| spellingShingle | Rebecca Hasseli Rebecca Hasseli Frank Hanses Melanie Stecher Christof Specker Tobias Weise Stefan Borgmann Martina Hasselberger Bernd Hertenstein Martin Hower Bimba F. Hoyer Carolin Koll Andreas Krause Marie von Lilienfeld-Toal Hanns-Martin Lorenz Uta Merle Susana M. Nunes de Miranda Mathias W. Pletz Anne C. Regierer Jutta G. Richter Jutta G. Richter Siegbert Rieg Christoph Roemmele Maria M. Ruethrich Tim Schmeiser Hendrik Schulze-Koops Anja Strangfeld Maria J.G.T. Vehreschild Florian Voit Reinhard E. Voll Jörg Janne Vehreschild Jörg Janne Vehreschild Ulf Müller-Ladner Alexander Pfeil The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries Frontiers in Medicine inflammatory rheumatic diseases COVID-19 general population tumor necrosis factor-alpha inhibitors severe disease |
| title | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| title_full | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| title_fullStr | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| title_full_unstemmed | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| title_short | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| title_sort | protective effect of tumor necrosis factor alpha inhibitors in covid 19 in patients with inflammatory rheumatic diseases compared to the general population a comparison of two german registries |
| topic | inflammatory rheumatic diseases COVID-19 general population tumor necrosis factor-alpha inhibitors severe disease |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1332716/full |
| work_keys_str_mv | AT rebeccahasseli theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT rebeccahasseli theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT frankhanses theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT melaniestecher theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT christofspecker theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT tobiasweise theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT stefanborgmann theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT martinahasselberger theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT berndhertenstein theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT martinhower theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT bimbafhoyer theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT carolinkoll theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT andreaskrause theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT marievonlilienfeldtoal theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT hannsmartinlorenz theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT utamerle theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT susanamnunesdemiranda theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mathiaswpletz theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT annecregierer theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT juttagrichter theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT juttagrichter theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT siegbertrieg theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT christophroemmele theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mariamruethrich theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT timschmeiser theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT hendrikschulzekoops theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT anjastrangfeld theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mariajgtvehreschild theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT florianvoit theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT reinhardevoll theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT jorgjannevehreschild theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT jorgjannevehreschild theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT ulfmullerladner theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT alexanderpfeil theprotectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT rebeccahasseli protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT rebeccahasseli protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT frankhanses protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT melaniestecher protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT christofspecker protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT tobiasweise protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT stefanborgmann protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT martinahasselberger protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT berndhertenstein protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT martinhower protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT bimbafhoyer protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT carolinkoll protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT andreaskrause protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT marievonlilienfeldtoal protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT hannsmartinlorenz protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT utamerle protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT susanamnunesdemiranda protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mathiaswpletz protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT annecregierer protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT juttagrichter protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT juttagrichter protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT siegbertrieg protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT christophroemmele protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mariamruethrich protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT timschmeiser protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT hendrikschulzekoops protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT anjastrangfeld protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT mariajgtvehreschild protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT florianvoit protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT reinhardevoll protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT jorgjannevehreschild protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT jorgjannevehreschild protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT ulfmullerladner protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries AT alexanderpfeil protectiveeffectoftumornecrosisfactoralphainhibitorsincovid19inpatientswithinflammatoryrheumaticdiseasescomparedtothegeneralpopulationacomparisonoftwogermanregistries |